These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7827172)

  • 21. Anti-oncogene ribozymes for cancer gene therapy.
    Irie A; Kijima H; Ohkawa T; Bouffard DY; Suzuki T; Curcio LD; Holm PS; Sassani A; Scanlon KJ
    Adv Pharmacol; 1997; 40():207-57. PubMed ID: 9217927
    [No Abstract]   [Full Text] [Related]  

  • 22. Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.
    Rossi JJ; Sarver N
    Adv Exp Med Biol; 1992; 312():95-109. PubMed ID: 1514448
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of ribozymes for gene therapy.
    Sullivan SM
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ; Yoon K; Moelling K; Coney LR
    Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.
    Grassi G; Forlino A; Marini JC
    Nucleic Acids Res; 1997 Sep; 25(17):3451-8. PubMed ID: 9254703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents.
    Scherr M; Grez M; Ganser A; Engels JW
    J Biol Chem; 1997 May; 272(22):14304-13. PubMed ID: 9162065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
    Koizumi M; Kamiya H; Ohtsuka E
    Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribozyme gene therapy: applications for molecular medicine.
    Lewin AS; Hauswirth WW
    Trends Mol Med; 2001 May; 7(5):221-8. PubMed ID: 11325634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA hairpin loops repress protein synthesis more strongly than hammerhead ribozymes.
    Drew HR; Lewy D; Conaty J; Rand KN; Hendry P; Lockett T
    Eur J Biochem; 1999 Nov; 266(1):260-73. PubMed ID: 10542074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases.
    Grassi G; Dawson P; Guarnieri G; Kandolf R; Grassi M
    Curr Pharm Biotechnol; 2004 Aug; 5(4):369-86. PubMed ID: 15320768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
    Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
    Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.